Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia
December 15, 2014 at 08:05 AM EST
Relypsa, Inc. (Nasdaq: RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug ...
